Dr. Carlos Dujovne MD
Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
Member of the Healthcare Council
Council Member Biography
Carlos Dujovne is the Professor of Medicine, the Chairman of Kansas Foundation for Clinical Pharmacology and Therapeutics (KFCPT), Cardiovascular Division and the Director of Clinical Cardiovascular and Metabolic Risk Treatment Programs at Oregon Health and Science University, in Portland, since July 2008. Dr. Dujovne, MD, is an Internist, Gastroenterologist, Clinical Pharmacologist, Certified Clinical Lipidologist, and was a Professor of Medicine & Pharmacology and the Director of Clinical Pharmacology's Lipid Arteriosclerosis Prevention Treatment Clinic in the Department of Medicine and Pharmacology at University of Kansas. He has conducted clinical trials for development of all lipid-regulating and anti-obesity drugs and food dietary fiber supplements. Dr. Dujovne has authored over 180 scientific articles and 16 book chapters. He is a founding member of Board of Directors of the National Lipid Association, member of AHA, ASPET and ASCPT. (This is me - Update Profile)
Employment History
- 2008 - Unspecified
- Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
- 1970 - 1998
- Professor of Medicine & Pharmacology, Director , UNIVERSITY OF KANSAS
GLG NewsSM Analyses by Carlos Dujovne(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 13, 2008
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com
1:Crestor is the most potent statin in the market,yet is 3d in sales behind Zocor and Lipitor.2:The efficacy supriority together with its capacity to lower CRP levels led to the highest rate of ASCVD prevention in the shortest period of time evr documented in statin trials.3:The trial in near 18,000 patients with otherwise lower risk of ASCVD offered $0% reduction y many ascvd endpoints.4:There were no statistical differences in side effect compared to placebo.5:The dosage was 20 mg /day (an intermediate dose below the approved max dose of 40 mg/day
-
September 29, 2008
Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
This article is not news for clinical researchers like myself that have performed hundreds of clinical trials in collaboration with the Pharmaceutical Industry. Some of the most common reasons for that are: A)Negative studies are difficult to get published.B)Negative results for the dug of the sponsor company are of potentially damaging financial for the sponsor.C)There is no FDA regulation that prohibits a sponsor to deny access to data and freedom of publication to Investigators of the trial not employed by them. Some of the possible solutions for these problems are:A)Complete freedom of access and publication of data by investigators.B)Sponsors of studies be obligated to submit result regardless of outcome,to FDA.C)Studies shall be easily searchable in a Google style manner at FDA files,by naming a company ,a drug ,a condition,etc,etc.
-
June 23, 2008
After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 | newsroom.lilly.com
More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.
-
February 19, 2008
China Plant Played Role | online.wsj.com
1:Most of our legislators are forcefully endorsing generic drug usage and importing cheaper drugs.2:As a physician specialist in Clinical Pharmacologist I am fully aware or the safety and efficacy pitfalls of poorly manufactured drugs and have done clinical research documenting the risks of patients treated with them.3:For that reason I strongly advised my patients to buy branded drugs by reputable Pharmaceutical Companies who have much to loose if found to manufacture poorly made drugs.
-
January 23, 2008
No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com
One, twenty years ago I was the chairman of the government affairs committee of the American Society for Clinical Pharmacology and Therapeutics; under that role my committee was successful lobbying for approval new investigational drugs for possible treatment of AIDS. We were successful in getting the FDA to approve the testing of those drugs to dying AIDS patients. Such approval led to the discovery and successful drugs we have available today for the treatment of AIDS. Two, This scenario can be easily applied to patients that are dying from any other incurable diseases where drugs that have the potential for serious toxicity cannot be ethically tested in human volunteers or patients with the same disease but not yet at a terminal stage.
Leading institutions connect with Carlos Dujovne through GLG
GLG Study Groups with Carlos Dujovne(?)
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| General Cardiologists (US) | 1327 |
| Gastroenterologists (US) | 803 |
| Physicians who Treat Hypertension (US) | 792 |
GLG Live Meetings with Carlos Dujovne(?)
Carlos Dujovne has not participated in any GLG Live Meetings.